Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer "Panthera"

NCT04042051 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT04042051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer "Panthera"
Lead sponsor
Cancer Trials Ireland
Phase
Phase 1
Overall status
Terminated
Start date
November 12, 2019
Completion date
November 2, 2020
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, locally advanced breast cancer, metastatic breast cancer, unresectable breast cancer